Viridian Therapeutics Inc...
(VRDN) ✕
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
undefined
undefined%
At close: undefined
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
Revenue | 314.00K | 1.77M | 2.96M | 1.05M | 4.46M | 8.39M | 4.00M | 3.34M | 2.54M | 4.32M | 4.32M | 4.41M |
Cost of Revenue | 1.32M | 755.00K | 620.00K | 28.30M | 32.79M | 30.42M | 19.62M | 2.55M | 2.47M | 3.24M | 2.50M | 3.04M |
Gross Profit | -1.01M | 1.02M | 2.34M | -27.25M | -28.33M | -22.04M | -15.62M | 789.00K | 66.00K | 1.08M | 1.82M | 1.36M |
Operating Income | -254.45M | -134.30M | -79.73M | -110.38M | -41.98M | -33.08M | -26.53M | -12.51M | -11.19M | -6.87M | -196.21K | -4.03M |
Interest Income | 18.56M | 4.92M | 318.00K | 173.00K | 941.00K | 1.25M | 403.00K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -237.73M | -129.87M | -79.41M | -110.72M | -41.87M | -32.70M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -5.62M |
Net Income | -237.73M | -125.44M | -79.42M | -110.98M | -42.42M | -32.70M | -26.51M | -12.67M | -11.33M | -7.89M | -2.16M | -7.21M |
Selling & General & Admin | 95.00M | 35.18M | 25.80M | 13.27M | 11.65M | 11.05M | 10.91M | 9.57M | 10.25M | 7.75M | 2.17M | 4.23M |
Research & Development | 159.76M | 100.89M | 56.89M | 28.30M | 34.79M | 30.42M | 19.62M | 888.00K | 1.00M | 293.00K | 96.85K | 225.38K |
Other Expenses | n/a | n/a | n/a | 69.86M | n/a | n/a | n/a | 2.83M | n/a | n/a | n/a | n/a |
Operating Expenses | 254.76M | 136.08M | 82.69M | 41.57M | 46.44M | 41.47M | 30.54M | 10.46M | 11.25M | 8.04M | 2.26M | 4.46M |
Interest Expense | 1.85M | 486.00K | 3.00K | 508.00K | 835.00K | 873.00K | 383.00K | 95.00K | 141.00K | 1.02M | 1.96M | 1.59M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1.67M | 2.56M | 717.00K | 378.77K | 1.33M |
Cost & Expenses | 254.76M | 136.08M | 82.69M | 41.57M | 46.44M | 41.47M | 30.54M | 13.01M | 13.72M | 11.29M | 4.76M | 7.50M |
Income Tax | n/a | -4.43M | 3.00K | 269.00K | 547.00K | 1.25M | 95.00K | 95.00K | n/a | 1.02M | 1.96M | 3.18M |
Shares Outstanding (Basic) | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.45K | 150.39K | 188.12K | 186.09K |
Shares Outstanding (Diluted) | 44.76M | 32.09M | 11.92M | 3.56M | 2.09M | 1.97M | 1.28M | 721.41K | 539.46K | 150.39K | 188.12K | 186.09K |
EPS (Basic) | -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
EPS (Diluted) | -5.31 | -3.91 | -6.66 | -31.2 | -20.31 | -16.57 | -20.66 | -17.57 | -21 | -52.46 | -11.48 | -38.75 |
EBITDA | -234.56M | -128.63M | -78.79M | -109.67M | -40.75M | -31.55M | -25.82M | -12.51M | -11.00M | -6.72M | -47.90K | -3.88M |
Depreciation & Amortization | 522.00K | 755.00K | 620.00K | 539.00K | 288.00K | 281.00K | 308.00K | 341.00K | 184.00K | 144.00K | 148.31K | 144.29K |